Eliem Therapeutics Inc (ELYM)
$3.09
$-0.14
(-4.33%)
As on 04-Dec-2024 09:30EDT
Market cap
$343 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
67,060,200
5 Years Aggregate
CFO
$-113.15 Mln
EBITDA
$-124.23 Mln
Net Profit
$-143.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eliem Therapeutics Inc (ELYM)
| 14.4 | -19.1 | -54.8 | 18.4 | -33.8 | -- | -- |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Eliem Therapeutics Inc (ELYM)
| -26.4 | -64.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eliem Therapeutics Inc (ELYM)
|
3.1 | 342.7 | 0.0 | -64.2 | -- | -38.9 | -- | 1.0 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Eliem Therapeutics Inc (ELYM)
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.... The company was incorporated in 2018 and is headquartered in Wilmington, Delaware. Read more
-
Principal Financial Officer & Executive Chairman
Dr. Andrew Levin M.D., Ph.D.
-
Principal Financial Officer & Executive Chairman
Dr. Andrew Levin M.D., Ph.D.
-
Headquarters
Wilmington, DE
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Eliem Therapeutics Inc (ELYM)
What is the current share price of Eliem Therapeutics Inc (ELYM) Today?
The share price of Eliem Therapeutics Inc (ELYM) is $3.09 (NASDAQ) as of 04-Dec-2024 09:30 EDT. Eliem Therapeutics Inc (ELYM) has given a return of -33.78% in the last 3 years.
What is the current PB & PE ratio of Eliem Therapeutics Inc (ELYM)?
Since, TTM earnings of Eliem Therapeutics Inc (ELYM) is negative, P/E ratio is not available.
The P/B ratio of Eliem Therapeutics Inc (ELYM) is 0.97 times as on 04-Dec-2024, a 81 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Eliem Therapeutics Inc (ELYM)?
The 52-week high and low of Eliem Therapeutics Inc (ELYM) are Rs -- and Rs -- as of 02-Sep-2026.
What is the market cap of Eliem Therapeutics Inc (ELYM)?
Eliem Therapeutics Inc (ELYM) has a market capitalisation of $ 343 Mln as on 04-Dec-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Eliem Therapeutics Inc (ELYM)?
Before investing in Eliem Therapeutics Inc (ELYM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.